Precigen Posts $35.8M Q3 Profit as Papzimeos Revenue Hits $72.9M
PGEN sits 64% above its 52-week low of $3.04 on elevated volume (1.9× avg).
Summary
Precigen earned $35.8 million in Q3 2026 on $74.1 million of revenue, almost all from Papzimeos, but cash fell to $51.0 million as $96.5 million sat in receivables. Three executives also set up new 10b5-1 sales plans.
Key Events · Earnings and Guidance · PGEN
-
Q3 Profit on Papzimeos Sales
Q3 2026 revenue was $74.1 million, including $72.9 million of Papzimeos product revenue, versus $2.9 million a year earlier. Net income was $35.8 million, or $0.10 per basic share.
-
Cash Tight Despite Profit
Cash, cash equivalents and investments totaled $51.0 million at September 30, 2026, down from $100.4 million at December 31, 2025, as trade receivables reached $96.5 million on 127-day Papzimeos payment terms.
-
Operating Cash Flow Turns Positive
Q3 2026 operating cash flow was positive $11.9 million, though the nine-month figure remained an outflow of $49.8 million.
-
Debt and Runway
$100 million principal outstanding on the Pharmakon term loan at a 12.5% effective rate, with eight quarterly $12.5 million principal payments beginning December 31, 2028. Management says liquidity plus Papzimeos collections funds at least one year.
Analysis · PGEN · Life Sciences
A second consecutive profitable quarter confirms Papzimeos is a real commercial product, not a launch promise: Q3 revenue of $74.1 million against $35.5 million of operating expenses produced $38.7 million of operating income. The catch is cash. Only $51.0 million of cash and investments remained at quarter-end because $96.5 million sits in receivables from a single wholesaler on 127-day payment terms, so reported profit runs well ahead of collected cash. Management says existing liquidity plus Papzimeos collections funds at least a year, but the $100 million Pharmakon term loan (12.5% effective rate, principal payments starting December 2028) and a stock near $5 keep dilution risk alive if collections slip. Separately, the CFO, COO and CCO all adopted new 10b5-1 selling plans effective late December 2026, adding a scheduled supply of shares over the next year.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PGEN was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $3.04 to $8.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.